GlassScriptPhysician profile
Joseph D Amos
NPI 1629012588
$29,209.08
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $326 · 2021: $344 · 2022: $249 · 2023: $1,412 · 2024: $52.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,013 · Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,012.52 |
| Food and Beverage | $451.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $23,577.32 | 2019-2022 | |
| Stryker Corporation | $1,281.71 | 2019 | |
| Intuitive Surgical, INC. | $1,058.49 | 2023 | Da Vinci Surgical System |
| Nevro Corp. | $632.72 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $369.28 | 2019 | |
| Davol INC. | $345.24 | 2019-2023 | Phasix Mesh, Arista Ah Flexitip |
| Biom'Up Sa | $294.06 | 2019 | |
| Allergan, INC. | $273.67 | 2019-2022 | |
| Abbott Laboratories | $234.62 | 2019-2020 | |
| Abbvie INC. | $145.37 | 2023-2024 | Alloderm, Strattice Reconstructive Tissue Matrix Bps |
| Astrazeneca Pharmaceuticals LP | $143.60 | 2022-2023 | Andexxa |
| Biom'Up France Sas | $137.37 | 2020 | |
| Mml US, INC. | $131.87 | 2023 | Reactiv8 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.41 | 2021 | |
| Heron Therapeutics, INC. | $82.29 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $75.21 | 2019-2021 | |
| Pfizer INC. | $60.76 | 2019-2020 | |
| Cook Medical LLC | $33.44 | 2020 | |
| Ethicon US, LLC | $33.35 | 2021 | |
| Avanos Medical | $26.20 | 2020 | |
| Becton, Dickinson and Company | $24.55 | 2021 | |
| Portola Pharmaceuticals, LLC | $24.24 | 2019 | |
| Tela Bio, INC. | $21.36 | 2022 | |
| Vertiflex, INC. | $20.70 | 2019 | |
| Kci USA, INC. | $19.31 | 2020 | |
| Z-Medica, LLC | $18.59 | 2019 | |
| Acell, INC. | $17.99 | 2019 | |
| Sanara Medtech INC. | $15.24 | 2022 | |
| Csl Behring | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Amos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.